Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia

Clinical Microbiology and Infection

Volumn 18, Issue 11, 2012, Pages

  Van der Bij, A K ^a,b   Van Dijk, K ^a,c   Muilwijk, J ^a   Thijsen, S F T ^d   Notermans, D W ^a   De Greeff, S ^a   Van de Sande Bruinsma, N ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b REINIER DE GRAAF HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Antimicrobial susceptibility breakpoints; Bacterial drug resistance; CLSI; Escherichia coli; EUCAST; Surveillance; Trends

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOOD SAMPLING; DISEASE SURVEILLANCE; ESCHERICHIA COLI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 84867709503     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03996.x     Document Type: Article

References (16)

1. O'Brien TF, Stelling J. Integrated multilevel surveillance of the world's infecting microbes and their resistance to antimicrobial agents. Clin Microbiol Rev 2011; 24: 281-295.
2. Jones RN, Masterton R. Determining the value of antimicrobial surveillance programs. Diagn Microbiol Infect Dis 2001; 41: 171-175.
3. Kahlmeter G, Brown DF, Goldstein FW et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 2003; 52: 145-148.
4. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI.
5. Kahlmeter G. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints. Clin Microbiol Infect 2008; 14 (Suppl 1): 169-174.
6. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI.
7. Leclercq R, Canton R, Giske C et al. Expert rules in antimicrobial susceptibility testing. Version 1. Availble at: http://www.eucast.org. (last accessed 2 July 2012).
8. Leclercq R, Canton R, Brown DF et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 2011; Oct 2012. doi: 10.1111/j.1469-0691.2011.03703.x [Epub ahead of print].
9. European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST breakpoint table version 1.0. Availble at: http://www.eucast.org. (last accessed 2 July 2012).
10. Hombach M, Bloemberg GV, Bottger EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J Antimicrob Chemother 2012; 67: 622-632.
11. European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST breakpoint table version 1.1. Available at: http://www.eucast.org. (last accessed 2 July 2012).
12. Hindler JF, Stelling J. Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis 2007; 44: 867-873.
13. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement; M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute.
14. Gagliotti C, Balode A, Baquero F et al. Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill 2011; 16: [Epub ahead of print].
15. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 2003; 24: 121-134.
16. Rhomberg PR, Jones RN. Summary trends for the Meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009; 65: 414-426.